© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
July 05, 2022
"A key overarching question is whether there is just a higher burden/stage of disease “beyond which we don’t think a bladder preservation is likely to provide durable disease control,” says Neil Desai, MD.
July 04, 2022
“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.
“Your best bladder is the one you were born with,” says Neil Desai, MD.
July 03, 2022
On this episode of Cleveland Clinic’s Cancer Advances podcast, Byron Lee, MD, PhD, discusses optimizing surgical options for patients with bladder cancer.
July 01, 2022
In the phase 1b COSMIC-021 trial, the combination of cabozantinib and atezolizumab showed clinical activity with manageable toxicity across several setting in urothelial carcinoma.
June 27, 2022
Based on previously reported CheckMate-274 data, the FDA approved nivolumab for the adjuvant treatment of patients with urothelial carcinoma.
June 23, 2022
Randomized controlled trial compares intracorporeal robotic technique with open surgery.
June 21, 2022
Guru P. Sonpavde, MD, discusses the 2022 ASCO Annual Meeting abstract, “Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.”
June 17, 2022
Sumanta K. Pal, MD, highlights next steps now that the combination of cabozantinib and atezolizumab showed promising clinical activity in bladder cancer in the phase 1b COSMIC-021 trial.
June 14, 2022
Guru P. Sonpavde, MD, highlights long-term data from the phase 3 EV-301 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.